+34 679 490 537info@nanbiosis.com

Posts Taged drive-project

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers.

The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of the Basque Country, led by José Luis Pedraz, Scientific Director of   NANBIOSIS Unit 10, Drug Formulation, which participates, through the CIBER BBN and the ICTS Nanbiosis, in the Drive Project  focused on pancreatic  cell transplantation  and the development of biomaterials and new surgical devices that improve the transplantation and survival of insulin-producing pancreatic islets for the treatment of diabetes.

Dr. Pedraz explained for EIBT.eus Radio euskadi the aim of the DRIVE project: the transplantation of the cells of the pancreas, which consists of isolating the insulin-producing cells from a donor’s pancreas and implanting them in the patient with daibetes type I, not directly, but introduced into an artificial bio-pancreas by minimal invasive surgery . “Nowadays– explains Dr. Pedraz- obtaining pancreatic cells from stem cells or IPS cells is a not yet controlled process but it is an alternative source of insulin-producing cells. In the DRIVE project the most priority objective is to take the donor cells and introduce them into a device that will allow the patient to produce and release insulin in a more physiological way. In a second phase, it is intended to use differentiated insulin producing cells from the patient’s own cells, thus alleviating the shortage of  donors”.

Read More

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with diabetes and relatives who want to participate. “One of the objectives of this meeting is to better understand the expectations of people with diabetes and their doubts about the treatment of that disease. By giving us their opinion, they will help us to adapt the DRIVE project to their needs“, explained the organization.
The event is organized by the NanoBioCel research group of the University of the Basque Country / Euskal Herriko Unibertsitatea, directed by José Luis Pedraz, Scientific Director of NANBIOSIS Unit 10, Drug Formulation, who participates in the DRIVE project through the CIBER BBN and the ICTS Nanbiosis, the only Spanish group in the project .
Admission is free and can be obtained at: https://www.ticketea.com/entradas-conferencia-drive-patient-panel/

 

Read More

“It is necessary to increase our relationship with European research groups” by José Luis Pedraz – U10 of NANBIOSIS

Last Sunday, November 27, the Newspaper of Álava published a special supplement with the title “ALAVA 2020”. It contained an article by José Luis Pedraz (Scientific Director of Unit 10 of NANBIOSIS)

According to Dr. Pedraz, group leader of the CIBER-BBN NANOBIOCEL group, in the next future, important challenges with new technologies will allow a considerable advance in the treatment of diseases of genetic origins. In this context, it is crucial to increase the number of international contacts in order to be able to access new infrastructures more competitively. The opening of new lines of research and the creation of new research infrastructure through consortiums such as CIBER-BBN or the Unique Scientific and Technologic Infrastructure (ICTS) NANBIOSIS generate an advantageous situation to attract new investments and create new companies. Pedraz continues explaining that we must increase our relations with European research groups in order to build consortia with which participate in for European research calls.

The NANOBIOCEL Group, coordinator of Unit 10 of NANBIOSIS, currently participates in two European consortiums (DRIVE Project) and (BERENICE Project) .

"It is necessary to increase our relationship with European research groups" by José Luis Pedraz - U10 of NANBIOSIS
Read More

Midyear meeting in Vitoria of European project DRIVE

CIBER-BBN participates in the project through NanoBioCel group, led by professor José Luis Pedraz Muñoz, Scientific Director of Unit 10 of NANBIOSIS, working on the optimization of formulations to be included in a bioartificial organ.

José Luis Pedraz Munoz and Jesus Izco coordinator of NANBIOSIS have participated in the meeting held in Vitoria on 3 and 4 of October.

The DRIVE objective is to develop new biomaterials and devices surgical transplantation and improve islet survival producing pancreatic insulin for the treatment of diabetes. Diabetes Mellitus is a chronic disease characterized by high blood glucose levels and affects 422 million people in the world, according to 2014 World Health Organization (WHO).

DRIVE is a four-year European project funded by the Horizon 2020 program for research and innovation of the Union European and endowed with 8.9 million euros. It is being conducted by 14 European partners and coordinated by the Royal College of Surgeons Ireland (Royal College of Surgeons in Ireland). Seeks to develop a bioartificial pancreas that is inserted into the body through minimally invasive techniques. To do this, they are being carried out preclinical studies to integrate this system in the human body and assess its effectiveness in people. The system will contain islets Pancreatic to restore the natural control of blood sugar and eliminate the need for multiple daily injections of insulin, thus improving the quality of life of patients.

Midyear meeting in Vitoria of European project DRIVE
Read More

Nanbiosis in the 2ª General Assambly of DRIVE project, Venice (16th-17th 2016)

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation  of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of  DRIVE project, held in Venice, May 16th-17th 2016.

The second General Assembly of European project DRIVE “DIABETES-REVERSING-IMPLANTS FOR ENHANCED VIABILITY AND LONG TERM EFFICACY”, took place last 16 and 17 of May in San Servolo Island, Venice. Jesus Ciriza, from NanoBioCel  group, presented the work scheduled for this first year and the results obtained.

The DRIVE, a 4-year project to be carried out by 14 European partners, among which is CIBER-BBN, develops biomaterials and new surgical devices to improve transplantation and survival of insulin-producing pancreatic islet for the treatment of diabetes.

CIBER-BBN participates in the project thought Unit 10 of NANBIOSIS with the role of:

-Development of hydrogel formulations for β-Gel

-Developing unlimited future sources of insulin-producing β-cells

-Testing β-cell function in β-Gel using 3D in vitro tissue model.

Jesus Izco, Coordinator of NANBIOSIS and José Luis Pedraz, Scientific Director of Unit 10-Drug Formulation of NANBIOSIS and NanoBioCel Group of CIBER-BBN, participated in the 2ª General Assambly of DRIVE project, held in Venice, May 16th-17th 2016.
Read More